Stock Track | Arvinas (ARVN) Plummets 5.11% Despite Beating Q4 Earnings Estimates, Revenue Miss Weighs

Stock Track

Feb 11, 2025

Arvinas Holding Company LLC (ARVN) stock plummeted 5.11% in the morning trading session on Tuesday, following the release of its fourth-quarter 2024 financial results. Despite beating earnings estimates, the biotech company missed revenue expectations, which likely contributed to the stock's decline.

For the quarter ended December 31, 2024, ARVN reported a net loss of $0.63 per share, narrower than the consensus estimate of a $0.96 loss per share. However, the company's revenue of $59.2 million fell short of analysts' expectations of $65.3 million.

On the positive side, ARVN provided an update on its cash runway, stating that its cash, cash equivalents, and marketable securities as of December 31, 2024, are sufficient to cover planned expenses and capital expenditures through 2027. This extended cash runway could provide the company with financial flexibility to advance its drug development programs and support operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1102373727"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102373727\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102373727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102373727","market":"us","top_or_hot":-1,"title":"Stock Track | Arvinas (ARVN) Plummets 5.11% Despite Beating Q4 Earnings Estimates, Revenue Miss Weighs","media":"Stock Track","content":"<p>Arvinas Holding Company LLC (ARVN) stock plummeted 5.11% in the morning trading session on Tuesday, following the release of its fourth-quarter 2024 financial results. Despite beating earnings estimates, the biotech company missed revenue expectations, which likely contributed to the stock's decline.</p>\n\n<p>For the quarter ended December 31, 2024, ARVN reported a net loss of $0.63 per share, narrower than the consensus estimate of a $0.96 loss per share. However, the company's revenue of $59.2 million fell short of analysts' expectations of $65.3 million.</p>\n\n<p>On the positive side, ARVN provided an update on its cash runway, stating that its cash, cash equivalents, and marketable securities as of December 31, 2024, are sufficient to cover planned expenses and capital expenditures through 2027. This extended cash runway could provide the company with financial flexibility to advance its drug development programs and support operations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arvinas (ARVN) Plummets 5.11% Despite Beating Q4 Earnings Estimates, Revenue Miss Weighs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arvinas (ARVN) Plummets 5.11% Despite Beating Q4 Earnings Estimates, Revenue Miss Weighs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-11 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arvinas Holding Company LLC (ARVN) stock plummeted 5.11% in the morning trading session on Tuesday, following the release of its fourth-quarter 2024 financial results. Despite beating earnings estimates, the biotech company missed revenue expectations, which likely contributed to the stock's decline.</p>\n\n<p>For the quarter ended December 31, 2024, ARVN reported a net loss of $0.63 per share, narrower than the consensus estimate of a $0.96 loss per share. However, the company's revenue of $59.2 million fell short of analysts' expectations of $65.3 million.</p>\n\n<p>On the positive side, ARVN provided an update on its cash runway, stating that its cash, cash equivalents, and marketable securities as of December 31, 2024, are sufficient to cover planned expenses and capital expenditures through 2027. This extended cash runway could provide the company with financial flexibility to advance its drug development programs and support operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARVN","symbol_name":"Arvinas Holding Company LLC","start_time":0,"source_url":"","article_id":"1102373727","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102373727","pubTimestamp":1739284801,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arvinas Holding Company LLC  stock plummeted 5.11% in the morning trading session on Tuesday, following the release of its fourth-quarter 2024 financial results. Despite beating earnings estimates, the biotech company missed revenue expectations, which likely contributed to the stock's decline.For the quarter ended December 31, 2024, ARVN reported a net loss of $0.63 per share, narrower than the consensus estimate of a $0.96 loss per share. However, the company's revenue of $59.2 million fell sh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARVN":"Arvinas Holding Company LLC"},"translate_title":"尽管第四季度盈利超出预期，但Arvinas(ARVN)仍暴跌5.11%，但营收未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARVN":1},"content_text":"Arvinas Holding Company LLC (ARVN) stock plummeted 5.11% in the morning trading session on Tuesday, following the release of its fourth-quarter 2024 financial results. Despite beating earnings estimates, the biotech company missed revenue expectations, which likely contributed to the stock's decline.\nFor the quarter ended December 31, 2024, ARVN reported a net loss of $0.63 per share, narrower than the consensus estimate of a $0.96 loss per share. However, the company's revenue of $59.2 million fell short of analysts' expectations of $65.3 million.\nOn the positive side, ARVN provided an update on its cash runway, stating that its cash, cash equivalents, and marketable securities as of December 31, 2024, are sufficient to cover planned expenses and capital expenditures through 2027. This extended cash runway could provide the company with financial flexibility to advance its drug development programs and support operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}